About geminismith
The Anti-HIgG(Fc)-C-DX8951 ADC represents a novel approach in antibody-drug conjugate (ADC) technology, designed to enhance the precision of cancer therapies. This ADC combines an anti-HIgG(Fc) antibody with the potent chemotherapeutic agent DX-8951, leveraging the specificity of the antibody to deliver the drug directly to target cells, thereby minimizing systemic toxicity.
No questions yet .